An erectile disfunction drug could be the next Alzheimers treatment

Maybe being bone-headed is a good thing.With over 900,000 people getting diagnosed with Alzheimer’s every year in the US, scientists are on the hunt for new and better treatments.And it turns out some remedies could be right under our noses (and in our nightstands).Yes: The beloved little blue pill, Viagra, has shown some promise sending blood to all the right places — like the brain, warding off dementia.And now, new research shows a related drug that’s long been used for erectile dysfunction in Korea could soon help with Alzheimer’s in the US.AdvertisementThe drug, called AR1001, uses a lower dose of mirodenafil, an ED treatment used in Korea since 2007, to potentially treat Alzheimer’s.A new clinical trial found it slowed cognitive decline by 31% — but only in a certain population.AR1001’s maker AriBio plans to apply for FDA approval in 2027, meaning this new research could pave the way for the drug to land on the US market in the next few years.
AdvertisementMirodenafil, the active ingredient in the new drug, and sildenafil, the active ingredient in Viagra, belong to the same class of drugs: PDE5 inhibitors.These work by controlling breakdown of a chemical messenger called cGMP, keeping muscles relaxed and improving blood flow.Normally, they’re prescribed to direct blood to the penis.But now, the drugs are being investigated for their ability to improve blood flow in the brain and improve cognitive function.AdvertisementBlood flow plays a key part in Alzheimer’s development.
Reduced blood flow allows toxic amyloid plaques to build up, and not enough oxygen and nutrients to supply brain cells.Unlike sildenafil, mirodenafil is not currently FDA approved for erectile dysfunction or any other use.But it has been approved in Korea for ED since 2007.The latest research was part of its phase 3 clinical trials to investigate its safety and efficacy for Alzheimer’s treatment.
It’s the last step before applying for FDA approval in the US.Advertise...